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Abstract: It takes more than 20 years before the human brain obtains its complex, adult 
configuration. Most dramatic developmental changes occur prenatally and early 
postnatally. During development, long-chain polyunsaturated fatty acids (LCPUFA) such 
as doxosahexaenoic acid (DHA) and arachidonic acid (AA) are accreted in the brain. Since 
breastfeeding is associated with a better developmental outcome than formula feeding, and 
human milk in contrast to traditional standard formula contains LCPUFA, the question 
arose whether LCPUFA supplementation of infant formula may promote the 
neurodevelopmental outcome. The current paper reviews the evidence available in   
full-term infants. It concludes that postnatal supplementation of formula with LCPUFA is 
associated with a beneficial effect on short-term neurodevelopmental outcome. However, 
no evidence is available that LCPUFA supplementation enhances neurodevelopmental 
outcome in full-term infants beyond the age of four months. Nevertheless, it should be 
realized that very limited information is available on the effect of LCPUFA 
supplementation on neurodevelopmental outcome at school age or later. It is conceivable 
that effects of LCPUFA supplementation first emerge or re-emerge at school age when 
more complex neural functions are expressed. 
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1. Introduction: Breastfeeding is Associated with Better Developmental Outcome 
More than 80 years ago, it had already been noted that breastfed infants had a better developmental 
outcome than infants fed other types of milk [1]. Now it is well established that breastfeeding is 
associated with a better neurological, cognitive and behavioral outcome than formula feeding [2-5]. 
However, it has not been clarified to which extent the composition of human milk explains this 
difference in development. For example, when perinatal and social confounders are taken into account, 
breastfeeding is associated with an increment of cognitive function of about 3 IQ points [4]. However, 
when the results are also adjusted for maternal IQ the cognitive benefit of breastfeeding is reduced to a 
small and non-significant difference of about 0.5 IQ points [6]. On the other hand, breastfeeding 
remained associated with a lower prevalence of fine manipulative dysfunction when maternal IQ was 
taken into account [3]. In addition, the finding that prolongation of the duration of breastfeeding – as a 
result of a cluster-randomized trial to promote breastfeeding – was associated with a better cognitive 
outcome at six years [7], suggests that the composition of human milk plays a role in the positive 
association between breastfeeding and outcome. Until recently, one of the differences between human 
milk and standard commercially available formulas was the presence of long-chain polyunsaturated 
fatty acids (LCPUFA) in human milk [8]. This fact inspired research on the effect of LCPUFA 
supplementation of formula in pre-term and full-term infants. The present paper aims at reviewing the 
effect of LCPUFA supplementation on neurodevelopmental outcome in full-term infants. The 
paragraphs reviewing the studies on the effect of LCPUFA supplementation are preceded by sections 
summarizing the ontogeny of the human brain and fatty acid accretion in the central nervous system. 
2. Ontogeny of the Human Brain 
The development of the human brain takes over 20 years. It is based on a continuous interaction 
between genetic information and environmental factors (for details on human brain ontogeny   
see  [9-11]). Genetic instructions are, for instance, the major driving forces behind the functional 
topography of the human brain [12]. Environmental influences may vary from external sensory 
experiences, sensory experiences generated by self-produced motor activity and effects of   
chemical substances. The latter may be generated endogenously by the body or obtained from the 
external world, such as nutritional substances. 
Brain development starts during the early phases of gestation with the proliferation of neurons in 
the germinal layers near the ventricles [13]. Next, neurons migrate in an orderly fashion to their final 
destinations. Meanwhile, they start to differentiate [14]. Neuronal differentiation includes the 
formation of dendrites and axons, the production of neurotransmitters and synapses, and the 
elaboration of the intracellular signaling machinery and the complex neural membranes [9,10]. The 
process of differentiation is particularly active in the few months prior to term age and the first few 
months post-term. The formation of synapses continues throughout life. Besides neural cells, glial cells 
are generated. The peak of glial cell production occurs in the second half of gestation [15]. Part of the 
glial cells take care of axonal myelination. Myelination takes place especially between the second 
trimester of gestation and the end of the first postnatal year. But it is first completed around the age of 
40 years [16]. A remarkable feature of brain development is that it does not only consist of creation of 




(apoptosis), in particular during mid-gestation [17]. Similarly, axons and synapses are eliminated, the 
latter especially between the onset of puberty and early adult age [18,19]. The shaping of the nervous 
system by these regressive phenomena is guided by neurochemical processes and neural activity [20]. 
The neural elements which fit the environment best persist, thus allowing for an adaptation of the brain 
to its own environment.  
Brain development is characterized by phases of transition. A major transition occurs around three 
to four months post-term [21-23]. At three to four months, the subplate, the transient cortical structure 
mediating fetal and neonatal behavior, has been largely replaced by the cortical plate [22]. The cortical 
changes are paralleled by changes in behavior [21]. For instance, motor behavior changes from 
motility dominated by non-goal directed general movements into goal directed motility such as 
reaching behavior [24].  
The continuous developmental changes in the brain have three practical implications for studies on 
the effect of LCPUFA supplementation. First, the effects of supplementation will depend on the timing 
of the supplementation. In other words, the effect of postnatal supplementation in pre-terms may differ 
from that in full-term infants. Second, the neurodevelopmental instruments to assess the effect of 
intervention should be age-specific. Third, the effects of supplementation on neurodevelopmental 
outcome in early infancy may differ from those on outcome at later age. Highly relevant for studies on 
the effect of nutritional intervention during early life is the finding that the development of neural 
dysfunction due to prenatal, perinatal or neonatal adversities may be characterized by phases in which 
dysfunction is not expressed. For instance, the Groningen Perinatal Project demonstrated that prenatal, 
perinatal and neonatal adversities were strongly associated with neonatal neurological morbidity. 
However, at the age of 18 months, the association between early risk factors and neurological 
dysfunction had disappeared to a large extent. It was first at school age, in particular from nine years 
onwards, that clear associations between early adversities and minor neurological dysfunction, 
learning and behavioral problems re-emerged [25].  
3. Fatty Acid Accretion in the Human Brain 
Fatty acids are major components of brain tissue: about 50 to 60% of dry adult brain weight consists 
of fatty acids [26]. Long-chain polyunsaturated fatty acids (LCPUFA), such as doxosahexaenoic acid 
(DHA; 22:6ω3) and arachidonic acid (AA; 20:4ω6) are amongst the most important fatty acids which 
are incorporated into the brain, in particular into the synaptic membranes [26-28]. Initially LCPUFA 
accretion in human neural tissue proceeds rather slowly [29]. An LCPUFA accretion spurt first occurs 
in the last trimester of gestation [30,31]. There is some evidence that accretion of AA in the brain 
during the last trimester exceeds that of DHA, so that at term age the brain contains relatively more 
AA than DHA [30,31]. After term age, LCPUFA accretion in the nervous system continues. Gradually 
accretion of DHA surpasses that of AA. As a result, DHA is the major LCPUFA in the adult brain. In 
the brain LCPUFA accumulate mainly in the cortical gray matter, in particular in the synaptic 
membranes, and to a lesser extent in the white matter [27,28]. The baboon study of Diau et al. [27] 
indicated that highest concentrations of DHA and AA are found in the precentral, postcentral, 
prefrontal and occipital cortices, basal ganglia, hippocampus, thalamus and cerebellum, a finding 
which suggests that LCPUFA intake might affect in particular circuitries involved in sensorimotor 




DHA and AA can be obtained directly from the diet or by endogeneous conversion of the parent 
precursors alpha-linolenic acid (ALA; 18:3ω3) and linoleic acid (LA; 18:2ω6) by means of chain 
elongation and desaturation. The fetus and newborn infant are capable of these conversion processes, 
but the enzymatic systems involved seem to be unable to supply sufficient LCPUFA to meet the high 
requirements until 16 weeks after term age [28]. This means that during early development, LCPUFA 
supply is largely dependent on dietary intake of DHA and AA. For the fetus, this implies that it is 
dependent on maternal intake of LCPUFA, while the young infant has to rely on LCPUFA   
in milk [32,33].  
4. LCPUFA Supplementation and Development in Full-Term Infants 
The systematic review of Simmer et al. [34] concluded that the RCTs on the effect of postnatal 
LCPUFA supplementation of formula milk in term infants did not show a beneficial effect of 
LCUPFA on neurodevelopmental outcome. However, this conclusion may be slightly modified when 
age at outcome is taken into account. The effect of LCPUFA supplementation on outcome in early 
infancy differs from that after the age of four months. This is illustrated in Table 1, which summarizes 
outcome until four months, and Table 2, which addresses outcome after the age of four months. The 
studies are rank ordered according to the level of DHA supplementation. Most studies evaluated visual 
development, cognitive or motor development. Table 1 shows that one of the three studies, in which 
formulae containing less than 0.30% DHA were evaluated, reported a better outcome in the 
supplemented infants, whereas seven out of eight studies in which formula with ≥0.30% DHA were 
used demonstrated a better developmental outcome in supplemented infants. On the basis of the 
limited number of studies, in particular those which studied the effect of relatively low DHA dosages, 
it can not be determined whether a beneficial effect of DHA supplementation on developmental 
outcome at early age depends on DHA dosage. Nevertheless, the ‘meta-regression analysis’ of   
Uauy et al. [35] suggested that the effect of postnatal LCPUFA supplementation in term infants on 
early visual development may be dependent on DHA dosage. It is also conceivable that a dosage of 
about 0.30% DHA may be sufficient to achieve the effect, as the recent study of Birch et al. [37] 
indicated that the effect of DHA on visual development was similar for supplementation with 0.32%, 
0.64% or 0.96% DHA. Table 2 indicates, however, that the positive effect of postnatal LCPUFA 
supplementation on developmental outcome could not be demonstrated for outcome after the age of 
four months. Nutrients 2010, 2                                       
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Table 1. LCPUFA supplementation in term infants and outcome until four months of age (adapted and updated from Hadders-Algra 2005 [36]). 
Author(s) Groups  Duration  of 
supplementation 







Carlson et al. 
1996 [37] 
E    n = 19 
C    n = 20 
BF  n = 19 
? 
 
BF ≥ 3 mo 
0.10%  0.43%  2 and 4   38%  Teller visual acuity 
[38] 
2 mo: E > C; BF > C 
4 mo: E = C; BF = C 
Auestad et al. 
1997 [39] 
a 
E1   n = 26 
E2   n = 28 
C    n = 28 
BF  n = 38 
≥ 4 mo 
 
 
BF ≥ 4 mo 
0.12% 
0.20% 
0.43%  2 and 4  39%  
(at 12 mo) 
FPL [40] 
Sweep VEP [41] 
E1 = C; E2 = C 
BF = C 
Auestad et al. 
2001 [42] 
E1   n = 58 
E2   n = 60 
C    n = 56 










1, 2 and 4  27% 
(at 12 mo) 
Teller visual acuity 
[38] 
E1 = C; E2 = C 
BF = C 
Agostoni et al. 
1995 [43] 
E    n = 27 
C    n = 29 
BF  n = 30 
4 mo 
 
BF ≥ 4 mo 
0.30%  0.44%  4  4%  Brunet – Lezine DQ 
[44] 
E > C 
BF > C 
Bouwstra et al. 
2003 [45]
b 
E    n = 131 
C    n = 119 
BF  n = 147 
2 mo 
BF variable; 
median 9 wk 
0.30% 0.45% 3  16% Quality  of  general 
movements [46] 
E > C 
BF > C 
Makrides et al. 
2000 [47] 
E1   n = 24 
E2   n = 23 
C    n = 21 




BF ≥ 3 mo 
0.34% 
0.35% 
0.34% 4    18% 
(at 8 mo) 
VEP [41]  E1 = C; E2 = C 
BF = C 
Makrides et al. 
1995 [48] 
E    n = 13 
C    n = 19 
BF  n = 23  
? 
 
BF ≥ 4 mo 
0.36%    4   11%  VEP [41]  E > C 




Table 1. Cont. 
Birch et al. 
1998 [49] 
E1   n = 23 
E2   n = 22 
C    n = 23 




BF ≥ 4 mo 
0.36% 
0.35% 
0.72%  1.5 and 4  18%  FPL [40] 
 
Sweep VEP [41] 
E = C; BF = C 
 
E1 > C; E2 > C 
BF > C 
Birch et al. 
2005 [50] 
E    n = 46 
C    n = 46 
12 mo  0.36%  0.72%  1.5 and 4 
 
4 
11% Sweep  VEP  [41] 
 
Stereoacuity [51] 
E > C 
 
E > C 
Ünay et al. 
2004 [52] 
E    n = 22 
C    n = 22 
BF  n = 23    
4 mo 
 
BF ≥ 4 mo 
0.50%    4  16%  BAEP [53]  E > C 
BF > C 
Birch et al. 
2010* [54] 
E1   n = 74  
E2   n = 75 
E3   n = 75 
C    n = 76 
12 mo  0.32% 
0.64% 
0.96% 
0.64%  1.5 and 4  12%  Sweep VEP [41]  E1 = E2 = E3 > C 
 
AA = arachidonic acid, BAEP = brainstem auditory evoked potential, BF = breast fed group, C = control group, DHA = docosahexaenoic acid, DQ = developmental quotient,  
E = experimental group, FPL = forced preference looking, FU = follow-up, mo = months, VEP = visual evoked potential. 
E = C: no statistically significant difference between experimental and control group; E > C: experimental group significantly better outcome than controls; E < C: experimental group 
significantly worse than control group. 
Superscript letters in authors column indicate that studies evaluated outcome in more or less the same study groups.  
* Birch et al. 2010: no exact numbers on assessed infants at each age available. 
Table 2. LCPUFA supplementation in term infants and outcome beyond 4 months (adapted and updated from Hadders-Algra 2005 [26]). 
Author(s) Groups  Duration  of 
supplementation 







Carlson et al. 
1996 [37] 
 
E    n = 19 
C    n = 20 
BF  n = 19 
? 
 
BF ≥ 3 mo 
0.10%  0.43%  6 and 12   ≥ 38%  Teller visual acuity 
[38] 
E = C 




Table 2. Cont. 




E1   n = 26 
E2   n = 28 
C    n = 28 
BF  n = 38 
≥ 4 mo 
 
 
BF ≥ 4 mo 
0.12% 
0.20% 
0.43%  6, 9 and 12  39%  
 
FPL [40] 
Sweep VEP [41] 
E = C 
BF = C 
Scott et al. 
1998 [55] 
a 
E1   n = 38 
E2   n = 33 
C    n = 42 
BF  n = 60 
≥ 4 mo 
 
 








Bayley PDI / MDI 
[56] 
McArthur language [57] 
E1 = C; E2 = C; BF = C 
 
E1 = C; E2 < C; BF = C 
Auestad et al. 
2001 [42] 
E1   n = 58 
E2   n = 60 
C    n = 56 










6, 9, 12 
 
6 and 9 
 
6 and 12 
 
6 and 12  
 
9 and 14 
27% 
(at 12 mo) 









E = C; BF = C 
 
E = C; BF = C 
 
E = C; BF = C 
 
E = C; BF = C 
 
E = C; BF = C 
Willats et al. 
1998 [60] 
E    n = 21 
C    n = 23 
4 mo  0.20  0.30  10   38%  Problem solving task [60]  E > C 
Auestad et al. 
2003 [61] 
a 
E1   n = 35 
E2   n = 35 
C    n = 37 











Teller vis. acuity  
Beery VMI [62] 
Stanford-Binet IQ [63] 
Language [57] 
E = C; BF = C 
E = C; BF = C 
E = C; BF = C 
 
E = C; BF = C 




E    n = 135 
C    n = 157 
BF  n = 154 
2 mo 
BF variable; 
median 9 wk 
0.30%  0.45%  18  6%  Hempel neurolog exam 
[65] 
Bayley PDI / MDI 
[56] 




Table 2. Cont. 




E    n = 91 
C    n = 123 
BF  n = 127 
2 mo 
BF variable; 
median 9 wk 
0.30% 0.45% 9  yr 28% Touwen  neurological 
exam 
[66] 
E = C; BF > C 
Agostoni et al. 
1997 [67] 
E    n = 26 
C    n = 30 
BF  n = 25 
4 mo 
 
BF ≥ 4 mo 
0.30%  0.44%  24  10%  Brunet – Lezine DQ 
[44] 
E = C; BF = C 
Lucas et al. 
1999 [68] 
E    n = 125 
C   n =  125 
BF n =  104 
6 mo 
 
BF ≥ 6 wk 
0.32% 0.30% 9 
 
18 
21%  Knobloch DQ [69] 
Bayley PDI / MDI 
[56] 
E = C; BF = C 
 
E = C; BF = C 
Singhal et al. 
2007 [70] 
E    n = 89 
C   n =  81 
BF n =  73 
6 mo 
 
BF ≥ 6 wk 
0.32% 0.30% 4-6  yr 
 
4-6 yr 
46%  Visual acuity [71] 
 
Stereoacuity [51] 
E = C; BF = C 
 
E = C; BF > C 
Makrides et al. 
2000 [47] 
E1   n = 19 
E2   n = 22 
C    n = 19 









12 and 24 
12% VEP  [41] 
 
Bayley PDI / MDI 
[56] 
E = C; BF = C 
 
PDI: E = C; BF = C 
12 mo MDI: E = C; BF = C;  
24 mo MDI: E = C; BF > C 
Birch et al. 
1998 [49] 
 
E1   n = 19 
E2   n = 22 
C    n = 20 




BF ≥ 4 mo 
0.36% 
0.35% 
0.72%  6 and 12  26% 
 
FPL [40] 
Sweep VEP [41] 
 
E = C; BF = C 
6 mo VEP: E = C;  
BF = C; 12 mo VEP:  
E1 > C; E2 > C; BF >C  
Birch et al. 
2000 [72] 
E1   n = 19 
E2   n = 17 
C    n = 20 
4 mo  0.36% 
0.35% 
0.72%  18   29%  Bayley PDI / MDI 
[56] 
MDI: E1 > C, E2 = C 
PDI: E = C 
Birch et al. 
2007 [50] 
E1   n = 19 
E2   n = 17 
C    n = 20 
BF  n = 32 
4 mo  0.36% 
0.35% 
0.72%  4 yr  34%  visual acuity [74] 
WPPSI [75] 
E1= C, E2 > C, BF > C 
VIQ: E = C, BF > C, E1 




Table 2. Cont. 
Birch et al. 
2005 [35] 
E    n = 42 
C    n = 44 
12 mo  0.36%  0.72%  9 and 12 
 
9 and 12 
17% Sweep  VEP  [41] 
 
Stereoacuity [51] 
E > C 
 
E = C 
Birch et al. 
2010* [54] 
E1   n = 64  
E2   n = 59 
E3   n = 65 
C    n = 56 
12 mo  0.32% 
0.64% 
0.96% 
0.64%  9 and 12  28%  Sweep VEP [41]  E1 = E2 = E3 > C 
 
Note that some of the studies of Table 2 are also included in Table 1; this implies that the groups were re-assessed after the age of four months. 
AA = arachidonic acid, BF = breast fed group, C = control group, DHA = docosahexaenoic acid, DQ = developmental quotient, E = experimental group, FPL = forced preference 
looking, FU = follow-up, IBQ = infant behavior questionnaire, IQ = intelligence quotient, MDI = mental developmental index, mo = months, PDI = psychomotor developmental index, 
VEP = visual evoked potential, VMI = visuomotor integration, WPPSI = Wechsler Preschool and Primary Scale of Intelligence 
E = C: no statistically significant difference between experimental and control group; E > C: experimental group significantly better outcome than controls; E < C: experimental group 
significantly worse than control group. 
Superscript letters in authors column indicate that studies evaluated outcome in more or less the same study groups.  
* Birch et al. 2010: no exact numbers on assessed infants at each age available. Nutrients 2010, 2                                       
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5. Concluding Remarks 
Postnatal supplementation of formula with LCPUFA in full-term infants is associated with a 
beneficial effect on short term neurodevelopmental outcome. Possibly, this short term beneficial effect 
is brought about by DHA levels of at least 0.30%. Interestingly, this putative threshold level is similar 
to the average level of DHA in human milk worldwide (0.32%, [8]). No long-term beneficial effects of 
LCPUFA supplementation in full-term infants have been demonstrated. However, it should be realized 
that very limited information is available on the effect of LCPUFA supplementation on 
neurodevelopmental outcome at school age or later. It is conceivable that effects of LCPUFA 
supplementation first emerge or re-emerge at school age when more complex neural functions   
are expressed. The latter possibility may be illustrated by the age-dependency of developmental 
differences between breastfed and formula-fed infants in the Netherlands. At the age of three months 
breast-fed infants have a better neurological condition than formula-fed infants [45], at 18 months this 
difference has disappeared [64], to re-emerge at the age of at least 3½ years [3,76]  
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